COPENHAGEN, Oct 2: Danish pharmaceutical group H Lundbeck and its Japanese partner, Takeda Pharmaceutical Co have submitted an application to the US Food and Drug Administration for approval of its antidepressant, vortioxetine, Lundbeck said today. Lundbeck is working to find replacements for its key anti-depressant, Cipralex, which is sold as Lexapro in the United States and Japan, as it comes off patent protection. The company has warned earnings will stall until 2015 due to cheap generic competition, meaning new products are key for future revenue growth. (agencies)
Follow our WhatsApp channel